Development of medicamentous therapy of ED – past, present and future

Czech version

Authors: V. Vyhnánková; D. Pacík; A. Čermák
Authors‘ workplace: Urologická klinika FN Brno a LF MU
Published in: Urol List 2014; 12(1): 19-23

Overview

Modern treatment of erectile dysfunction consists mainly of PDE5 inhibitors as the drugs of first choice. They are the easiest to administer with a quick effect. This includes sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra) and avanafil (Stendra). Second‑line therapy includes intracavernous or intraurethral submission of prostaglandin. Other modern methods, such as gene therapy, are also promising, but further studies are needed for their validation and application in practice.

Key words:
erectile dysfunction, PDE5 inhibitors, PGE1 prostaglandin

Sources

1. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342(24): 1802– 1813.

2. Šrámková T. Denní terapie erektilní dysfunkce – pro koho a s jakými riziky? Interní Med 2011; 13(6): 275– 278.

3. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151(1): 54– 61.

4. Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother 2009; 9(3): 341– 350. doi: 10.1586/ 14737175.9.3.341.

5. Bronner G, Royter V, Korczyn AD et al. Sexual dysfunction in Parkinson’s disease. J Sex Marital Ther 2004; 30(2): 95– 105.

6. Breza J. Erektilné poruchy. Martin: Osveta 1994.

7. Arcimovičová J. Drogy, které rozněcují vášně. Bulletin národní protidrogové centrály 4/ 2000: 10– 12.

8. Michal V, Kramár R, Pospíchal J. Femoro‑pudendal by‑ pass, internal iliac thromboendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Bull Soc Int Chir 1974; 33(4): 343– 350.

9. Kubíček V. Medikamentózní léčba erektilní dysfunkce – dramatická změna v přístupu k léčbě. Urol pro Praxi 2004; 2: 67– 71.

10. Vyhánková V, Pacík D. Tadalafil v léčbě LUTS/ BPH a ED. Urol List 2013; 11(1): 11– 14.

11. Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the treatment of non‑neurogenic male LUTS. European Association of Urology. Available from: http:/ / www.uroweb.rg/ gls/ pdf/ 12 Male_LUTS.pdf.

12. Kubíček V. Tadalafil (cialis) – nový inhibitor PDE‑ 5 v léčbě erektilní dysfunkce. Interní Med 2003; 1: 10– 13.

13. Setter SM, Iltz JL, Fincham JE et al. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39(7– 8): 1286– 1295.

14. Kuthe A. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Curr Opin Urol 2003; 13(5): 405– 410.

15. Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004; 64(23): 2667– 288.

16. Goldstein I, Lue TF, Padma‑ Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20): 1397– 1404.

17. De Bon E, Bonanni G, Saggiorato G et al. Eff ects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. Angiology 2010; 61(6): 602– 606. doi: 10.1177/ 0003319710362977.

18. Porst H, Giuliano F, Glina S et al. Evaluation of the efficacy and safety of once‑ a‑ day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double‑blind, placebo‑ controlled trial. Eur Urol 2006; 50(2): 351– 359.

19. Crowe SM, Streetman DS. Vardenafil treatment for erectile dysfunction. Ann Pharmacother 2004; 38(1): 77– 85.

20. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double‑blind, placebo‑ controlled trial. J Androl 2002; 23(6): 763– 771.

21. Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid‑ onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010; 19(11): 1427– 1437. doi: 10.1517/ 13543784.2010.518955.

22. The long‑term safety of alprostadil (prostaglandin‑E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol 1998; 82(10): 538– 543.

23. European medicines agency. EPAR – Summary for the public. Available from: http:/ / www.ema.europa.eu/ docs/ cs_CZ/ document_library/ EPAR_Summary_for_the_public/ human/ 002581/ WC500145208.pdf.

24. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil – a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9(4): 187– 192.

25. Stief CG, Wetterauer U, Schaebsdau FH et al. Calcitonin‑gene‑related peptide: a possible role in human penile erection and its therapeutic application in impotent patients J Urol 1991; 146(4): 1010– 1014.

26. Song LJ, Pan LJ, Xu YM. Reconstuction of penile function with tissue engineering techniques. Zhonghua Nan Ke Xue 2007; 13(4): 352– 355.